Loading...
Loading...
Rosetta Genomics Ltd.
ROSG, a leading developer and
provider of microRNA-based molecular diagnostics, announces that the
Company has executed credentialing agreements with FedMed, Inc.
(FedMed) and Fortified Provider Network Inc. (FPN) for Rosetta's
Cancer Origin Test(TM).
FedMed is a Preferred Provider Organization (PPO) with over 550,000
physicians, 4,000 hospitals and 60,000 Ancillary Care Providers
nationwide. It is estimated that more than 40 million Americans have
access to FedMed's National Provider Network. FPN is a national
direct-contracted preferred provider network that represents
approximately four million covered lives. FPN's select provider
network is utilized by self-funded employer groups, insurance
carriers and regional and local provider networks that process
end-user patient claims.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in